Avacta Group plc, the developer of Affimer biotherapeutics and reagents, has entered into a collaboration with the Liverpool School of Tropical Medicine (LSTM) to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing with Cytiva.    Under the terms of the collaboration, LSTM will carry out the clinical validation of the Avacta COVID-19 antigen rapid saliva test in their category 3 laboratories on patient samples. In addition to working with the UK governm...